Novacyt Regulatory News (NCYT)

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Publication of Annual Report and AGM voting

Paris, France and Camberley, UK - 1 June 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2021 has been published and uploaded to the Company's website. The Annual Report has been posted to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs).

The Company's Annual General Meeting ("AGM") will be held as an open online meeting at 1pm BST/2pm CEST on Tuesday, 21 June 2022. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

The Notice of AGM and a Form of Proxy are available on the Company's website, together with AGM registration details and a video explaining the voting process to shareholders. All materials can be found at www.novacyt.com/investors.

Shareholders can register for the AGM and access the online meeting by visiting https://novacyt.eventcaster.co.uk. Registrations must include an electronic signature and be accompanied by proof of shareholding by 10.59pm BST/11.59pm CEST on Thursday 16 June 2022.

Shareholders are strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the Notice of AGM.

Shareholders can vote in advance of the AGM until 3pm BST/4pm CEST on Monday 20 June 2022 by:

· Downloading a copy of the Proxy voting form from www.novacyt.com/investors for completion and return to investor.relations@novacyt.com together with evidence of their holding.

· Voting on-line using the AGM portal https://novacyt.eventcaster.co.uk together with an electronic signature and proof of shareholding.

· Voting on-line using the Votaccess portal http://www.actionnaire.cic-marketsolutions.eu  if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank or JP Morgan.

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, at least 20% of shareholders must vote on the ordinary resolutions and 25% of shareholders must vote on the extraordinary resolutions.

Following registration and proof of shareholding, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish. Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors. Shareholders who have already voted (through a proxy, using the AGM or Votaccess portals) will be allowed to attend the AGM but will not be able to vote twice.

- End -

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com  

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com  

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com